(NASDAQ: CALC) Calcimedica's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.64%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.1%.
Calcimedica's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast CALC's revenue for 2026 to be $90,216,966, with the lowest CALC revenue forecast at $90,216,966, and the highest CALC revenue forecast at $90,216,966. On average, 2 Wall Street analysts forecast CALC's revenue for 2027 to be $280,854,007, with the lowest CALC revenue forecast at $218,024,335, and the highest CALC revenue forecast at $343,683,680.
In 2028, CALC is forecast to generate $919,890,850 in revenue, with the lowest revenue forecast at $571,374,118 and the highest revenue forecast at $1,268,407,582.